^ 4.04.1Fluorouracil topical. The American Society of Health-System Pharmacists. [2016-12-08]. (原始内容存档于2016-12-26).
^Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. The Journal of Dermatological Treatment. 2009, 20 (6): 328–335. PMID 19954388. S2CID 218896998. doi:10.3109/09546630902789326.
^British national formulary : BNF 69 69. British Medical Association. 2015: 590. ISBN 9780857111562.
^World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^Park H. J., Choi Y. T., Kim I. H., Hah J. C.; A case of reversible dementia associated with depression in a patient on 5-FU or its analogue drugs. J. Korean Neuropsychiatr. Assoc. 1987;30:199–202.
^ 28.028.1Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. Critical Reviews in Oncology/Hematology. March 1999, 30 (1): 71–79. PMID 10439055. doi:10.1016/s1040-8428(98)00036-5.
^Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. European Journal of Cancer. September 2002, 38 (13): 1677–1684. PMID 12175683. doi:10.1016/s0959-8049(02)00151-x.
^Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. Journal of the National Cancer Institute. December 2002, 94 (24): 1883–1888. PMID 12488482. doi:10.1093/jnci/94.24.1883.
^ 31.031.131.2Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clinical Colorectal Cancer. December 2012, 11 (4): 263–267. PMID 22683364. doi:10.1016/j.clcc.2012.05.004.
^ 32.032.1Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clinical Colorectal Cancer. September 2011, 10 (3): 203–206. PMID 21855044. doi:10.1016/j.clcc.2011.03.015.
^ 33.033.1Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, Lundell GD, McMillin G, Milano G, Salamone SJ. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Therapeutic Drug Monitoring. December 2009, 31 (6): 688–694. PMID 19935361. S2CID 220558482. doi:10.1097/FTD.0b013e3181b9b8c0.
^Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. The Oncologist. January 2007, 12 (1): 38–50. PMID 17227899. S2CID 21638678. doi:10.1634/theoncologist.12-1-38.
^van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics. May 2013, 14 (7): 799–811. PMID 23651027. doi:10.2217/pgs.13.54.
^Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. Journal of Clinical Oncology. May 2008, 26 (13): 2099–2105. PMID 18445839. S2CID 9557055. doi:10.1200/jco.2007.13.3934.
^Ma WW, Saif WM, Cartwright TH, Fakih M, El-Rayes BF, King T, Vanas J, von Borstel R, Bamat MK, Posey J. Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.. Journal of Clinical Oncology. 2016-05-20, 34 (15_suppl): e21689. ISSN 0732-183X. doi:10.1200/JCO.2016.34.15_suppl.e21689.
^Fluorouracil and Pet Safety. Office of the Commissioner. U.S. Food and Drug Administration (FDA). 2024-08-09 (英语).
^ 45.045.1Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. September 2011, 12 (9): 1321–1336. PMID 21919607. doi:10.2217/pgs.11.72.
^Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews. Cancer. May 2003, 3 (5): 330–338. PMID 12724731. S2CID 4357553. doi:10.1038/nrc1074.
^Álvarez P, Marchal JA, Boulaiz H, Carrillo E, Vélez C, Rodríguez-Serrano F, Melguizo C, Prados J, Madeddu R, Aranega A. 5-Fluorouracil derivatives: a patent review. Expert Opinion on Therapeutic Patents. February 2012, 22 (2): 107–123. PMID 22329541. S2CID 2793746. doi:10.1517/13543776.2012.661413.
^Sneader W. Drug discovery: a history.. John Wiley & Sons. June 2005: 255.
^Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. March 1957, 179 (4561): 663–666. Bibcode:1957Natur.179..663H. PMID 13418758. S2CID 4296069. doi:10.1038/179663a0.
^Jordan VC. A Retrospective: On Clinical Studies with 5-Fluorouracil. Cancer Research (American Association for Cancer Research). February 2016, 76 (4): 767–768. PMID 26880809. doi:10.1158/0008-5472.CAN-16-0150.
^Xu XH, Yao GM, Li YM, Lu JH, Lin CJ, Wang X, Kong CH. 5-Fluorouracil derivatives from the sponge Phakellia fusca. Journal of Natural Products. February 2003, 66 (2): 285–288. PMID 12608868. doi:10.1021/np020034f.